Summary:The fiscal year 2025 (FY25) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) mechanism supports advanced translational research that will accelerate the movement of promising ideas in Duchenne muscular dystrophy (DMD) research into clinical applications. Research must address at least one of the FY25 CTRA focus areas. Research projects investigating therapies that will be efficacious across the life span, including infants, toddlers, and nonambulatory individuals, are stron...